Business Context and Reporting Period
This Form 8-K Current Report was filed by DaVita Inc. on March 9, 2021. The filing serves as a Regulation FD disclosure in connection with the company's participation in the 2021 Barclays Global Healthcare Conference. The report focuses on providing updated data regarding the impact of the COVID-19 pandemic on DaVita's U.S. dialysis patient population and the progress of vaccination efforts for both patients and teammates.
Key Financial Metrics and Operational Data
The filing does not contain specific financial statements, revenue figures, profit margins, debt levels, or cash flow data. Instead, it provides operational metrics related to the pandemic as of late February and early March 2021:
- Active Cases: As of February 27, 2021, active COVID-19 cases among U.S. dialysis patients decreased by 70% from the peak prevalence on January 6, 2021.
- Incidence Rate: The last-seven-day incidence rate decreased by 84% from the week ending January 9, 2021, to the week ending February 27, 2021.
- Mortality Trends: Incremental mortality related to COVID-19 appeared to peak in mid-January 2021 and declined through the end of February 2021.
- Teammate Vaccination: As of March 8, 2021, approximately 50% of U.S. clinic-based teammates had received at least one vaccine dose.
- Patient Vaccination: As of March 8, 2021, approximately 28% of U.S. dialysis patients had received at least one vaccine dose.
Material Changes and Trends
DaVita reports that COVID-19 case numbers among its patient population have correlated closely with national trends in the general population. The filing highlights a significant material improvement in health metrics compared to the peak of the pandemic in early January 2021, with substantial declines in both active cases and incidence rates. The company notes that mortality trends generally trail incidence rates by two to four weeks.
Guidance, Outlook, and Risks
Guidance: DaVita is maintaining the 2021 guidance ranges provided in its fourth quarter 2020 earnings release on February 11, 2021.
Management Commentary: The company continues to monitor the pandemic's impact on operating and financial performance. Management emphasizes that the ultimate impact remains uncertain due to factors such as new virus strains, vaccine efficacy, and economic conditions. The company is advocating for direct federal allocation of vaccine supplies to improve accessibility for patients and teammates.
Risks and Contingencies: The filing outlines significant risks, including:
- Continued impact of the pandemic on revenue and growth due to lower treatment volumes.
- Potential negative impact on commercial mix from an extended economic downturn.
- Downward pressure on payment rates from commercial payors and potential reductions in government payment rates.
- Regulatory changes, healthcare reform, and legal compliance risks.
- Liquidity risks regarding the ability to service indebtedness and refinance debt.
Investor Verification Checklist
- Verify the specific 2021 financial guidance ranges referenced from the February 11, 2021, earnings release.
- Monitor the trajectory of vaccination rates for patients and teammates, noting the variability based on local distribution policies.
- Assess the potential impact of new virus strains on the current downward trend in incidence and mortality rates.
- Review the company's exposure to commercial payor mix changes and potential reimbursement rate reductions.
- Confirm the company's liquidity position and debt refinancing capabilities given the stated risks regarding cash flow variability.